The present disclosure provides methods and pharmaceutical compositions for treating ulcerative colitis (UC) in a subject in need thereof. In particular, the compositions described here comprise or are designed based on fecal bacteria associated with FMT-based UC treatment success or failure. Also provided are methods for screening patients for their suitability for a fecal bacteria-based UC treatment. Further provided are methods for screening fecal donors for optimized source materials for producing a fecal bacteria-based pharmaceutical composition.

The invention relates to a method for labeling specifically living microorganisms in a sample comprising microorganisms, the method comprising the steps of: a) incubating said microorganisms of said sample with at least one modified monosaccharide compound comprising a first reactive chemical group capable to chemically react with a second reactive group, so that a residue bearing said first reactive group is incorporated into such microorganisms, and b) contacting said residue incorporated in the microorganisms, with a labeling molecule comprising a said second reactive group, for generating the chemical reaction of said first reactive group of said residue incorporated within said living microorganisms with said second reactive group of said labeling molecule, resulting in a covalent link, characterized in that the said modified monosaccharide compound has the following formula (I′), or a salt thereof: —X can be O, NH or S, preferably O and NH, and —R1 and R2 can be independently H, OH, NH.sub.2, OH and NH.sub.2 being substituted or not by protecting groups thereof, preferably substituted by alkyl, hydroxyalkyl, acyl, formyl or imidoyl groups, and —R3 is H or an alkyl chain in C.sub.1 to C.sub.4, each carbon being substituted or not substituted by OH or NH.sub.2 substituted or not by protecting groups thereof, preferably by alkyl, hydroxyalkyl, acyl, formyl or imidoyl groups, and —at least one of X, R1, R2 and R3 groups, preferably R3, being substituted by a said first reactive group Ra. ##STR00001##

Methods for rapidly concentrating a food sample for efficient detection of bacteria are disclosed. A microfiltration approach followed by centrifugation was used to concentrate the cells with an enzyme (e.g., a protease) added at the beginning of the process to facilitate more efficient micro-filtering. The enzyme was found to have no significant effect on cell viability.

[OBJECT] To enable accurate identification of a specific serotype of Salmonella bacteria in a method for analyzing a microorganism using a MALDI-MS. [MEANS FOR SOLVING PROBLEM] The present invention is a method for analyzing a microorganism including an identification step for determining which of Abony and Pakistan which are two serotypes of Salmonella bacteria is contained in a sample which contains either Abony or Pakistan, based on the presence or absence of a peak (or peaks) at a predetermined mass-to-charge ratio (or ratios) in a mass spectrum obtained by a mass spectrometric analysis of the sample, or a method for analyzing a microorganism including an identification step for determining which of Minnesota. Infantis and Brandenburg which are three serotypes of Salmonella bacteria is contained in a sample which contains Minnesota. Infantis or Brandenburg, based on the presence or absence of a peak (or peaks) at a predetermined mass-to-charge ratio (or ratios) in a mass spectrum obtained by a mass spectrometric analysis of the sample, or a method for analyzing a microorganism including an identification step for determining which of Schwarzengrund and Montevideo which are two serotypes of Salmonella bacteria is contained in a sample which contains either Schwarzengrund or Montevideo, based on the presence or absence of a peak (or peaks) at a predetermined mass-to-charge ratio (or ratios) in a mass spectrum obtained by a mass spectrometric analysis of the sample.

The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.

The invention relates to allergic disease, to the development of allergic disease in infants, to determining the likelihood of development of allergic disease in infants and to minimizing the likelihood of development of allergic disease in infants.

Described herein are engineered microbe-targeting or microbe-binding molecules, kits comprising the same and uses thereof. Some particular embodiments of the microbe-targeting or microbe-binding molecules comprise a carbohydrate recognition domain of mannose-binding lectin, or a fragment thereof, linked to a portion of a Fc region. In some embodiments, the microbe-targeting molecules or microbe-binding molecules can be conjugated to a substrate, e.g., a magnetic microbead, forming a microbe-targeting substrate (e.g., a microbe-targeting magnetic microbead). Such microbe-targeting molecules and/or substrates and the kits comprising the same can bind and/or capture of a microbe and/or microbial matter thereof, and can thus be used in various applications, e.g., diagnosis and/or treatment of an infection caused by microbes such as sepsis in a subject or any environmental surface. Microbe-targeting molecules and/or substrates can be regenerated after use by washing with a low pH buffer or buffer in which calcium is insoluble.

Described herein are antigen-binding molecules that bind to bacteria (e.g., Listeria monocytogenes) and methods of use thereof. Also described herein are compositions and kits comprising these antigen-binding molecules.

A method for evaluating a plate including a plurality of wells, the method including: an injection step of injecting an evaluation sample including a cell and a test substance into the plurality of wells, the evaluation sample being adjusted in advance so that a foreign matter is generated as a result of cell death caused by the test substance; a counting step of counting the number of wells having the foreign matter among the plurality of wells at a first counting timing at which a first predetermined time has elapsed since the evaluation sample is injected into the plurality of wells; and a determination step of determining that the plate is appropriate when the number of wells having the foreign matter among the plurality of wells is one or more, and determining that the plate is inappropriate when the number of wells having the foreign matter is zero.

Provided herein are systems and methods for characterizing target/ligand engagement. In particular, luciferase-labeled polypeptide targets are used to detect or quantify target/ligand engagement (e.g., within a cell or cell lysate).